Why is "Apixaban" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-26 19:35:53
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Apixaban entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-26 and was most recently seen on 2026-08-26.
Wikipedia Overview
Apixaban, sold under the brand name Eliquis among others, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa. It is used as an alternative to warfarin to prevent blood clots following hip or knee replacement and in those with a history of prior clots and does not require monitoring by blood tests or dietary restrictions. It is taken by mouth.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism - The New England Journal of Medicine
-
Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk - 2 Minute Medicine
-
Apixaban bests rivaroxaban in new DOAC comparison - Cardiovascular Business
-
Safer blood clot treatment with apixaban than with rivaroxaban, according to large venous thrombosis trial - EurekAlert!
-
Apixaban Bests Rivaroxaban for Bleeding in VTE: COBRRA - TCTMD.com
-
Apixaban May Cut Stroke Risk but Raise Bleeding in Dialysis Patients - Medscape
-
Apixaban Snags a Win in Head-to-Head Trial of Direct Oral Anticoagulants - MedPage Today
-
Apixaban safer than rivaroxaban for thrombosis treatment, study finds - The Pharmaceutical Journal
-
Transfer of Apixaban into Human Milk : Obstetrics & Gynecology - Lippincott Home
-
Unilateral Arm Swelling on Apixaban: Central Venous Thrombosis Missed by Point-of-Care Ultrasound - Cureus
-
For Patients With Provoked VTE and at Least One Ongoing Risk Factor, 12 Months of Apixaban Is Better Than 3 Months - American Academy Of Family Physicians | AAFP
-
Predictors Highlighted for Bleeding During Extended Apixaban for Cancer-Associated VTE - Docwire News
-
Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial - Kamel - Annals of Neurology - Wiley Online Library
-
11 Eliquis (Apixaban) Interactions You Should Know About - GoodRx
-
Apixaban blood thinner associated with more time at home among older adults, study finds - McKnights Home Care
-
Apixaban reduces bleeding risk versus rivaroxaban in acute venous thromboembolism - 2 Minute Medicine
-
As Direct Oral Anticoagulants Face Off in VTE Trial, Apixaban Confirmed as a Safer Option - Medscape
-
Apixaban linked to lower risk of recurrent blood clots compared with warfarin - The Pharmaceutical Journal
-
Apixaban in Patients with Atrial Fibrillation - The New England Journal of Medicine
-
Safety and Efficacy of Apixaban in HeartMate 3 Left Ventricular Assist Devices - Pillai - 2026 - Clinical Transplantation - Wiley Online Library
-
Apixaban Safe and Effective for Provoked VTE - Docwire News
-
Apixaban May Offer a 'Practical Alternative' for Dialysis Patients With Afib - MedPage Today
-
Teva fails to overturn patent for BMS’ apixaban in Russian market - The Pharma Letter
-
Apixaban reduces complications, helps older adults spend more time at home after blood clots - News-Medical
-
Coroner highlights lack of head injury warnings for anticoagulant - The Pharmaceutical Journal
-
Study Proves Favourable Safety of Apixaban Over Rivaroxaban - EMJ
-
Bleeding risk lower with apixaban vs. rivaroxaban for venous thromboembolism - Healio
-
2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026] - 2 Minute Medicine
-
Greater Risk of Serious Bleeding With Diltiazem vs. Metoprolol in Adults With Atrial Fibrillation Using Apixaban or Rivaroxaban - American Academy Of Family Physicians | AAFP
-
Grieving widow's warning over blood thinners - BBC
-
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company - Business Wire
-
Maculopathy Risk With Use of Apixaban, Paclitaxel, Ibrutinib, Sildenafil - Optometry Advisor
-
Watch Out for Bleeding in These Cancer Patients on Extended Anticoagulation - MedPage Today
-
Blood-thinning drug Eliquis likely safer for patients with deep blood clots, study suggests - CBC
-
Concurrent Superior Mesenteric and Splenic Vein Thrombosis in a Prothrombin G20210A Carrier: Radiologic Evolution and Resolution on Apixaban - Cureus
-
Recurrent Ischaemic Stroke in a Patient With Left Ventricular Thrombus Despite Apixaban: Successful Transition to Warfarin - Cureus
-
Apixaban-Induced Leukocytoclastic Vasculitis: An Uncommon Complication of a Common Anticoagulant - Cureus
-
Patients with atrial fibrillation face higher bleeding risks when treated with 2 common medications - Medical Xpress
-
Can you stop blood thinners after an ablation for atrial fibrillation? - Harvard Health
-
Eliquis Market Outlook Signals Continued Revenue Stability at 4.6% CAGR - Market.us Media
-
Conservative Management With Tranexamic Acid for Intrahepatic Pseudoaneurysm After Unsuccessful Biliary Drainage in a Patient on Apixaban - Cureus
-
Safety and Efficacy of Direct Oral Anticoagulants as Thromboprophylaxis in Patients With Multiple Myeloma Receiving a Lenalidomide-Based Induction Regimen - Journal of Hematology Oncology Pharmacy
-
Anticoagulant Reversal Drug Pulled From U.S. Market - MedPage Today
-
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation - The New England Journal of Medicine
-
Development of maculopathy associated with systemic medications - Ophthalmology Times
-
Drugs Recognized as Potential Maculopathy Risk Factors - Review of Optometry
-
Apixaban versus Aspirin for Embolic Stroke of Undetermined Source - NEJM Evidence
-
Asundexian versus Apixaban in Patients with Atrial Fibrillation - The New England Journal of Medicine
-
Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve - NEJM Evidence
-
Can I take Apixaban and Levomepromazine together? - Patient.info
-
Letter 146 Apixaban is safer and more effective than rivaroxaban for non-valvular atrial fibrillation - National Institutes of Health (NIH) | (.gov)
-
Practice-changing evidence from academic trials in VTE: COBRRA, RENOVE, and API-CAT | Vasa - Hogrefe eContent
-
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism - The New England Journal of Medicine
-
Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial - American Heart Association Journals
-
Apixaban No Better Than Aspirin for Preventing Stroke Recurrence in Patients with Atrial Cardiopathy - WCM Newsroom
-
Apixaban Shows Lower Bleeding Risk In VTE - EMJ
-
Effectiveness and Safety of Edoxaban Compared With Apixaban in Elderly Patients With Nonvalvular Atrial Fibrillation: A Real-World Population-Based Cohort Study - American Heart Association Journals
-
Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned - American Heart Association Journals
-
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer - The New England Journal of Medicine
-
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer - The New England Journal of Medicine
-
Coroner urges review of apixaban leaflets after head trauma death - Pharmacy Magazine
-
Optimal Prescription of the Lower Dose of Apixaban∗: - JACC Journals
-
Ideal Apixaban Dose for Cancer-Associated VTE - The ASCO Post
-
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease | Circulation - American Heart Association Journals
-
Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding - Nature
-
MHRA issues alert for Sandoz Apixaban batches - Pharmacy Business
-
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: - American Heart Association Journals
-
Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States - American Heart Association Journals
-
Oral Apixaban for the Treatment of Acute Venous Thromboembolism - The New England Journal of Medicine
-
Kidney Function and Apixaban - Docwire News
-
Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy - American Heart Association Journals
-
Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation - Nature
-
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients - The New England Journal of Medicine
-
Anticoagulation in Atrial Fibrillation Patients With Frailty: - JACC Journals
-
ASCO Guidelines Strongly Recommend Apixaban for VTE in Cancer - CancerNetwork
-
Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: - American Heart Association Journals
-
Apixaban shows lowest major bleeding risk in older adults with HIV and atrial fibrillation - European AIDS Treatment Group
-
COBRRA Trial: Apixaban Shows Lower Bleeding Risk Than Rivaroxaban in Acute VTE - Medical Dialogues
-
Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF - TCTMD.com
-
Apixaban for End-Stage Kidney Disease: - American Heart Association Journals
-
Eliquis (Apixaban) Market Size, Share, Growth | CAGR of 4.6% - Market.us
-
Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis - Wiley Online Library
-
Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest - TCTMD.com
-
Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding - TCTMD.com
-
Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs - The American Journal of Managed Care
-
ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure - TCTMD.com
-
Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors - News-Medical
-
Large Desmoid Fibromatosis of the Breast Invading the Chest Wall - The American College of Surgeons
-
ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy - TCTMD.com
-
The best anti-clotting drug for afib? - Harvard Health
-
PROACT Xa: Apixaban Is Not a Safe Warfarin Substitute With Mechanical Aortic Valve - Cleveland Clinic
-
Apixaban for Extended Treatment of Venous Thromboembolism - The New England Journal of Medicine
-
Clot time ratio (CTR) and treatment outcomes in Apixaban-treated atrial fibrillation patients - Nature
-
Taho Pharma’s apixaban oral strips equivalent to Eliquis in pivotal trial - Clinical Trials Arena
-
Ibrutinib-Related Atrial Fibrillation: An Anticoagulant Challenge - Journal of Hematology Oncology Pharmacy
-
Coroner issues urgent apixaban blood thinner warning after 'minor fall' led to death of 'healthy' man - Manchester Evening News
-
Asundexian inferior to apixaban as anticoagulation therapy for atrial fibrillation - 2 Minute Medicine
-
New ARISTOTLE Data ‘Reassuring’ on Lower Apixaban Dose - TCTMD.com
-
Apixaban-Induced Spontaneous Hemorrhagic Cardiac Tamponade - Cureus
-
Long-term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices - Wiley Online Library
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.